Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 5/100

Failure Rate

0.0%

0 terminated/withdrawn out of 8 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

38%

3 trials in Phase 3/4

Results Transparency

100%

8 of 8 completed trials have results

Key Signals

8 with results

Enrollment Performance

Analytics

Phase 1

4(50.0%)

Phase 3

3(37.5%)

Phase 2

1(12.5%)

8Total

Phase 1(4)

Phase 3(3)

Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials

NCT02158572Phase 3Completed

Efficacy, Safety and Tolerability Study of Agile AG200-15 Transdermal Contraceptive Delivery System

Role: lead

NCT01422135Phase 1Completed

Pharmacokinetic Study of AG200-15 Transdermal Patch to Three Anatomical Sites in Healthy Females

Role: lead

NCT01375946Phase 1Completed

Pharmacokinetic Study Of AGILE AG200-15 After Weekly Application Under Various Conditions in Healthy Female Volunteers

Role: lead

NCT01250210Phase 2Completed

Evaluation of Pharmacodynamic Effects on Ovulation and Cycle Control

Role: lead

NCT01181479Phase 3Completed

Study to Evaluate the Contraceptive Efficacy/Safety of a Low Dose EE/LNG Transdermal Contraceptive Delivery System

Role: lead

NCT01243580Phase 1Completed

AG200-15 Transdermal Contraceptive Delivery System (TCDS) of Levonorgestrel and Ethinyl Estradiol

Role: lead

NCT01623466Phase 1Completed

Study to Evaluate Pharmacokinetics Profile, Wearability, and Safety of 2 Progestin-Only Patches

Role: lead

NCT01236768Phase 3Completed

Transdermal Contraceptive Delivery System (TCDS), Also Known as AG200-15 Patch Arm

Role: lead

All 8 trials loaded